Abstracts Archive - Page 838 of 2425 - ACR Meeting Abstracts

Abstract Number: 1194 • 2019 ACR/ARP Annual Meeting
Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?
Sarah Abu Mehsen ¹, Isabel Castrejon ¹ and Theodore Pincus², ¹Rush University Medical Center, Chicago, IL, ²Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Adverse events of medications have been reported to account for 5% of hospital admissions in the US, and as many as 10% in the…
Abstract Number: 1195 • 2019 ACR/ARP Annual Meeting
Quantitative Physician Global Assessment of Damage And/or Distress, in Addition to Inflammation, at Routine Rheumatology Care: Documenting the Complexity of Rheumatology Patient Encounters as a Rationale for Possible Higher Reimbursement?
Theodore Pincus¹, Isabel Castrejon ² and Joel A. Block ², ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Quantitative clinical measures and indices such as DAS28, CDAI, SLEDAI, BASDAI, are designed to assess inflammation, reflecting a goal to prevent long-term damage, and…
Abstract Number: 1196 • 2019 ACR/ARP Annual Meeting
Patient Preference for an Electronic MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/ Routine Assessment of Patient Index Data), Which Gives Similar Results Compared to a Paper Version
Theodore Pincus¹, Mariam Riad ¹, Elena Obreja ², Candice Lewis ² and Isabel Castrejon ², ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, chicago, IL
Background/Purpose: A self-report multi-dimensional health assessment questionnaire (MDHAQ) includes RAPID3 (routine assessment of patient index data), which is informative in all rheumatic diseases in which…
Abstract Number: 1197 • 2019 ACR/ARP Annual Meeting
Factors Associated with Clinical Disease Activity Index Adoption at an Academic Rheumatology Practice
Tarun Sharma¹, Kevin Wetherington ², Lori Mcaninch ², Abdalhamid Al Harash ¹, Nagadarshini Vinod ², Sonia Manocha ³, Adam Dore ³, Michael Lucke ³, William Ayoub ¹ and Mary Chester Wasko ⁴, ¹Allegheny Health Network, Pittsburgh, PA, ²AHN, Pittsburgh, ³Allegheny Health Network, pittsburgh, ⁴Allegheny Health Network-West Penn Hospital, Pittsburgh, PA
Background/Purpose: The 2015 American College of Rheumatology (ACR) guidelines for the treatment of rheumatoid arthritis (RA) strongly recommend using a treat-to-target (T2T) strategy that has…
Abstract Number: 1198 • 2019 ACR/ARP Annual Meeting
Practice Based Education Program to Increase Vaccination Rate in Patients on Immunotherapeutic Agents
Andrea Soliman¹, Soorya Aggarwal ¹, Kyle Kreitman ¹, Kourtney Erickson ¹, Abdul Aleem ¹ and Marie O'Brien ¹, ¹Lehigh Valley Health Network, Allentown, PA
Background/Purpose: Immunosuppressive agents have changed the course of debilitating autoimmune conditions. Despite their advantages, these agents come with risk of vaccine preventable infections.1 Multiple organizations recommend…
Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Nancy Desai¹, Hanni Menn-Josephy ¹, Ramon Bonegio ¹, Christina Lam ¹, Anna Kancharla ¹ and Michael York ¹, ¹Boston Medical Center, Boston
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…
Abstract Number: 1200 • 2019 ACR/ARP Annual Meeting
Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital
Judith Aniekwena¹, Titilope Olanipekun ² and Valery Effoe ², ¹Morehouse School of Medicine, Atlanta, GA, ²Morehouse School of Medicine, Atlanta
Background/Purpose: Influenza infection constitutes a significant cause of morbidity and mortality in patients living with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The risk…
Abstract Number: 1201 • 2019 ACR/ARP Annual Meeting
Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?
Claire Barber¹, Natalie Shiff ², Cheryl Barnabe ³, Susanne Benseler ³, Ricky Chin ³, Nicole Johnson ³, Nadia Luca ³, Paivi Miettunen ⁴, Marinka Twilt ³, Dwaraka Veeramreddy ³ and Heinrike Schmeling ⁵, ¹University of Calgary, Calgary, Canada, ²University of Florida, Gainesville, FL, ³University of Calgary, Calgary, AB, Canada, ⁴Alberta Children's Hospital, Calgary, ON, Canada, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Wait time to pediatric rheumatology care for patients with Juvenile Idiopathic Arthritis (JIA) is a nationally endorsed quality measure in Canada. Target wait times…
Abstract Number: 1202 • 2019 ACR/ARP Annual Meeting
Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies
Claire Barber¹, Dianne Mosher ², Glen Hazlewood ¹, Paul MacMullan ², Cheryl Barnabe ², Victoria Bohm ², James Rankin ², Joanne Homik ³, Kelly English ⁴, Karen Tsui ⁵, Bo Pan ⁶, Martina Stevenson ², Namneet Sandhu ², Andrea Emrick ², Liam Martin ¹, Caylib Durand ², Michelle Jung ² and Diane Lacaille ⁷, ¹University of Calgary, Calgary, Canada, ²University of Calgary, Calgary, AB, Canada, ³University of Alberta, Edmonton, Canada, ⁴Arthritis Patient Advocacy Board, Vancouver, BC, Canada, ⁵Arthritis Patient Advisory Board, Toronto, ON, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: The purpose of this study was to operationalize and report on 3 Rheumatoid Arthritis (RA) performance measures previously identified in the Patient-Centered Framework for…
Abstract Number: 1203 • 2019 ACR/ARP Annual Meeting
Psychometric Properities of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review
M. Elaine Husni¹, Mark Kosinski ², Regina Rendas-Baum ², Shelly Kafka ³, Chenglong Han ⁴, Eric K H Chan ⁴, Elizabeth Hsia ⁵ and Arthur Kavanaugh ⁶, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Optum, Johnston, RI, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁶University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Fatigue is an important patient reported outcome in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) research. FACIT-Fatigue is a 13-item patient reported outcome (PRO)…
Abstract Number: 1204 • 2019 ACR/ARP Annual Meeting
Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial
M. Elaine Husni¹, Diane Harrison ², Elizabeth Hsia ³, Eric K H Chan ², Chenglong Han ², Shelly Kafka ⁴, Kim Hung Lo ², Lilianne Kim ² and Arthur Kavanaugh ⁵, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: In the randomized, phase 3, GO-VIBRANT study, more patients with psoriatic arthritis (PsA) achieved ACR 20/50/70 after 24 weeks IV treatment with the anti-TNFa…
Abstract Number: 1205 • 2019 ACR/ARP Annual Meeting
Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Susan J. Bartlett ², Marie-France Valois ³, Louis Bessette ⁴, Gilles Boire ⁵, Glen Hazlewood ⁶, Carol Hitchon ⁷, Edward Keystone ⁸, Janet Pope ⁹, Carter Thorne ¹⁰, Diane Tin ¹¹, Vivian Bykerk ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹University of Toronto, Montreal, Canada, ²McGill University, Montreal, QC, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec City, QC, Canada, ⁵Sherbrooke University, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ⁹Western University, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Southlake Regional Health Centre, Newmarket, Canada, ¹²Hospital for Special Surgery, New York City, NY, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Early RA diagnosis and initiation of DMARDs following a treat-to -target approach is recommended to optimize remission outcomes. Several RA disease activity indices are…
Abstract Number: 1206 • 2019 ACR/ARP Annual Meeting
Performance of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Item Profile in a Cohort of Australians with RA, OA and Other Inflammatory Arthritic Conditions
Geraldine Hassett ¹, Dana Gerogevsky ², Joseph Descallar ³, Ray Fang ⁴, Frank Huang ⁴ and Kathryn Gibson¹, ¹Liverpool Hospital, Sydney, New South Wales, Australia, ²Royal Prince Alfred Hospital, Sydney, Australia, ³Ingham Research Institute, Sydney, New South Wales, Australia, ⁴University of New South Wales, Sydney, New South Wales, Australia
Background/Purpose: Guarded support for PROMIS-29 assessment in musculoskeletal disease has been reported in RA, OA, FM and SLE patients1. The performance of PROMIS-29 compared to…
Abstract Number: 1207 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Intervention to Reduce 30-Day Hospital Readmission Rates Among Patients with Systemic Lupus Erythematosus
Emily Bowers¹, Melissa Griffith ¹, Elena Weinstein ¹, Duane Pearson ¹ and Jason Kolfenbach ¹, ¹University of Colorado Department of Rheumatology, Denver, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic immune-mediated disease with significant morbidity and mortality that often requires inpatient hospitalization. SLE has one of the…
Abstract Number: 1208 • 2019 ACR/ARP Annual Meeting
Outpatient Readmission in Rheumatology: A Machine Learning Predictive Model of Patient’s Return to the Clinic
Luis Rodríguez-Rodríguez¹, Alfredo Madrid García ¹, Judit Font Urgelles ², Mario Vega-Barbas ³, Leticia León ⁴, Dalifer Freites Nuñez ⁵, Cristina Lajas ⁶, Esperanza Pato Cour ⁶, Juan Angel Jover Jover ⁶, Benjamín Fernández Gutiérrez ⁷ and lydia Abasolo Alcazar ⁶, ¹Fundación para la Investigación Biomedica, Madrid, Spain, ²HOSPITAL CLINICO SAN CARLOS, MADRID, Madrid, Spain, ³Universidad Politécnica de Madrid, Madrid, Madrid, Spain, ⁴Fundación para la Investigación Biomedica, Madrid, Madrid, Spain, ⁵Hospital Clínico San Carlos, MADRID, Spain, ⁶HOSPITAL CLINICO SAN CARLOS, MADRID, Spain, ⁷Hospital Clínico San Carlos, Madrid
Background/Purpose: Readmissions can be defined as the return of a patient to a healthcare setting after a discharge. Attention has been mainly focused on readmissions…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].